New combo therapy targets hard-to-treat liver metastases in colorectal cancer
NCT ID NCT06199232
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial tests a personalized treatment plan for people with advanced colorectal cancer that has spread to the liver and stopped responding to standard treatments. The approach combines a liver-directed chemotherapy (HAIC), a targeted therapy (fruquintinib or cetuximab), and an immunotherapy drug (tislelizumab). The study aims to see if this combination can help control the cancer for at least 6 months. It includes 47 participants whose tumors are microsatellite stable (MSS), a type that typically does not respond well to immunotherapy alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tislelizumab (immunotherapy) plus fruquintinib or cetuximab (targeted therapy) plus hepatic arterial infusion chemotherapy (HAIC)
What this could lead to
If successful, this could offer a new treatment option for people with advanced colorectal cancer that has spread to the liver and stopped responding to standard therapies.
What could go wrong
This is a small, early-phase trial with only 47 participants, so results may not apply to everyone. The combination therapy also carries risks of side effects from chemotherapy, targeted drugs, and immunotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER METASTASIS COLON CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking Univerisity Cancer Hospital
Beijing, Beijing Municipality, 100142, China